Table 3.
Gene | Pathogenic | Likely Pathogenic | LoF | Splice | Missense | Inframe deletion |
---|---|---|---|---|---|---|
MYBPC3 | 101 (27.1%) | 47 (12.6%) | 81 (21.7%) | 39 (10.5%) | 23 (6.2%) | 5 (1.3%) |
MYH7 | 75 (20.1%) | 33 (8.8%) | 0 | 0 | 106 (28.4%) | 2 (0.5%) |
TPM1 | 21 (5.6%) | 9 (2.4%) | 0 | 0 | 30 (8.0%) | 0 |
TNNI3 | 7 (1.9%) | 4 (1.1%) | 0 | 0 | 11 (2.9%) | 0 |
JPH2 | 10 (2.7%) | 0 | 0 | 0 | 10 (2.7%) | 0 |
TNNT2 | 7 (1.9%) | 2 (0.5%) | 0 | 0 | 7 (1.9%) | 2 (0.5%) |
RAF1 | 3 (0.8%) | 5 (1.3%) | 0 | 0 | 8 (2.1%) | 0 |
GLA | 3 (0.8%) | 3 (0.8%) | 2 (0.5%) | 0 | 4 (1.1%) | 0 |
Variant types and classification of likely pathogenic and pathogenic variants in genes in which more than five variants were detected. Percentages represent the proportion of total variants identified (n = 373)
LP for likely pathogenic, P for pathogenic, LoF for Loss of function, Splice for consensus splice site variant or other variant with known or suspected effect on splicing. A total of five splice variants were at a position greater than ± 10 bp from the intron/exon boundary